CrystalGenomics on Thursday said it has partnered with fellow Korean company Dong-A ST to market the osteoarthritis drug Acelex (polmacoxib) in Korea in a deal worth up to 8.5 billion South Korean won ($7.2 million).
The Korea-based biotechnology company said under the terms of the agreement it will also share profit from sales of Acelex.
Joong Myung Cho, chief executive of CrystalGenomics, said: "Dong-A ST's solid sales and marketing infrastructure makes them an ideal commercial partner for us in Korea."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze